Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Axovant
Axovant
Sio Gene could be a canary in the coalmine for gene therapy
Sio Gene could be a canary in the coalmine for gene therapy
EP Vantage
Sio Gene
Axovant
gene therapy
Flag link:
In quick start to new year's M&A, Arvelle Therapeutics hands reins to Angelini as it nears EU approval for cenobamate
In quick start to new year's M&A, Arvelle Therapeutics hands reins to Angelini as it nears EU approval for cenobamate
Endpoints
Arvelle Therapeutics
Angelini Pharma
M&A
CNS
epilepsy
cenobamate
Axovant
Flag link:
Axovant Changes Name to Sio Gene Therapies, Adding to List of Biopharma Company Rebrands
Axovant Changes Name to Sio Gene Therapies, Adding to List of Biopharma Company Rebrands
BioSpace
Axovant
Sio Gene Therapies
gene therapy
rebranding
Flag link:
Upcoming events – Avadel takes on Jazz and Axovant awaits early results
Upcoming events – Avadel takes on Jazz and Axovant awaits early results
EP Vantage
Avadel
FT218
Jazz Pharmaceuticals
Xyrem
Axovant
gene therapy
Parkinson's Disease
narcolepsy
Flag link:
Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival
Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival
Endpoints
Axovant
Alzheimer's disease
Roivant
Vivek Ramaswamy
Urovant
vibegron
urinary incontinence
Flag link:
Axovant trumpets new clinical data after gene therapy pivot
Axovant trumpets new clinical data after gene therapy pivot
Fierce Biotech
Axovant
gene therapy
Parkinson's Disease
Tay Sachs
Flag link:
Axovant axes neuroscience drug, focuses on gene therapies
Axovant axes neuroscience drug, focuses on gene therapies
Pharmaforum
Axovant
intepirdine
nelotanserin
gene therapy
Flag link:
Axovant dumps nelotanserin in retreat from small molecule R&D
Axovant dumps nelotanserin in retreat from small molecule R&D
Fierce Biotech
Axovant
nelotanserin
dementia with Lewy bodies
clinical trials
R&D
small molecule drugs
Flag link:
Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline
Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline
Endpoints
Axovant
gene therapy
Flag link:
Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica
Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica
CP Wire
Axovant
Oxford BioMedica
AXO-Lenti-PD
Pro-Savin
Flag link:
Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica
Axovant
Oxford BioMedica
Flag link:
The stint that never happened? Biotech vet David Hung wipes Axovant from his work history
The stint that never happened? Biotech vet David Hung wipes Axovant from his work history
Stat
David Hung
Axovant
Flag link:
David Hung makes a quick, abrupt exit at Axovant after humiliating setbacks
David Hung makes a quick, abrupt exit at Axovant after humiliating setbacks
Endpoints
David Hung
Axovant
Flag link:
The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug
The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug
Stat
Alzheimer's disease
Axovant
David Hung
dimebon
Medivation
intepirdine
Flag link:
Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s
Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s
EP Vantage
GSK
shingles
vaccines
Shingrix
Axovant
Alzheimer's disease
intepirdine
Flag link:
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
EP Vantage
R&D
Kite Pharma
Incyte
Portola Pharmaceuticals
DBV Technologies
Axovant
AveXis
Flag link:
3 Small Biotech Stocks Being Run by Proven Winners
3 Small Biotech Stocks Being Run by Proven Winners
Motley Fool
biotech
Axovant
Esperion Therapeutics
Aurinia Pharmaceuticals
Richard Glickman
David Hung
Roger Newton
Flag link:
Key FDA Decision And Trial Dates In February
Key FDA Decision And Trial Dates In February
Seeking Alpha
FDA
Amgen
Valeant Pharmaceuticals
Amphastar
Egalet
Lexicon Pharmaceuticals
Amicus Therapeutics
Axovant
Flag link:
Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies
Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies
TheStreet.com
Eli Lilly
Alzheimer's disease
solanezumab
AC Immune
Axovant
Biogen
Merck
Roche
Flag link:
Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug
Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug
Forbes
physicians
Axovant
Alzheimer's disease
RVT-101
GSK
Flag link:
Pages
1
2
next ›
last »